J&J laying off 400 in marketing overhaul

With Procrit under siege, Johnson & Johnson wants to divert its promotional efforts elsewhere--a strategy that will lead to some 400 job cuts in its sales-and-marketing ranks. The company told employees it would consolidate sales-and-marketing operations of Ortho Biotech and Centocor and shave the payroll accordingly.

With Procrit sales sinking ever since the FDA put new safety warnings on its class of anemia drugs, J&J wants to "free up resources that can be redeployed to opportunities that will make the greatest difference to patients and to our own future success as a business." Translation: Heavily marketing Procrit won't help that drug, so why not concentrate sales efforts somewhere we can see some ROI?

- read the Star-Ledger article

Related Articles:
Johnson & Johnson - Top 8 layoffs of 2007
Ranks of sales reps thinning
U.S. R&D headcount tumbles in key categories

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.